We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Respiratory Medicine

Journal Scan / Research · September 09, 2020

Efficacy and Safety of Sildenafil Added to Pirfenidone in Patients With Advanced Idiopathic Pulmonary Fibrosis and Risk of Pulmonary Hypertension

The Lancet Respiratory Medicine

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Respiratory Medicine
Efficacy and Safety of Sildenafil Added to Pirfenidone in Patients With Advanced Idiopathic Pulmonary Fibrosis and Risk of Pulmonary Hypertension: A Double-Blind, Randomised, Placebo-Controlled, Phase 2b Trial
Lancet Respir Med 2020 Aug 18;[EPub Ahead of Print], J Behr, SD Nathan, WA Wuyts, N Mogulkoc Bishop, DE Bouros, K Antoniou, J Guiot, MR Kramer, KU Kirchgaessler, M Bengus, F Gilberg, A Perjesi, S Harari, AU Wells

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading